Noile-Immune Biotech Inc.
Research Noile-Immune Biotech Inc. (4893.T) on Bullrun: market cap JPY 4.08B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker4893.T
- ExchangeTSE
- CountryJapan
- SectorHealthcare
- IndustryBiotechnology
- CurrencyJPY
- Market capJPY 4.08B
- Financial periodFY2025
- RevenueJPY 5.00M
- Revenue growth-34.1%
- Net income-JPY 793.54M
- Free cash flow-JPY 752.22M
- Gross margin100.0%
Valuation Snapshot
latest market cap is JPY 4.08B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | JPY 5.00M | -JPY 793.54M | -JPY 752.22M | 100.0% | -18.33 | JPY 3.92B | n/a | JPY 3.93B |
| FY2024 | JPY 7.59M | -JPY 964.46M | -JPY 887.81M | 97.4% | -22.28 | JPY 4.67B | n/a | JPY 4.73B |
| FY2023 | JPY 316.82M | -JPY 1.13B | -JPY 873.08M | 99.3% | -27.25 | JPY 5.56B | n/a | JPY 5.69B |
| FY2022 | JPY 625.78M | -JPY 386.62M | -JPY 107.18M | 98.9% | -9.87 | JPY 4.52B | n/a | JPY 4.30B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | JPY 4.08B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 JPY.
About Noile-Immune Biotech Inc.
Noile-Immune Biotech Inc. researches and develops CAR-T cells for novel cancer immunotherapies. The company's product pipeline includes, NIB101, a target antigen for solid tumors; NIB102, a next-generation CAR-T cell therapy; NIB103, autologous CAR-T cell therapy for mesothelin (MSLN); NIB104, a PRIME technology against target antigens in solid tumors; ADAP01; AUTL01; and CHUG01. Noile-Immune Biotech Inc. was incorporated in 2015 and is headquartered in Minato, Japan.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Noile-Immune Biotech Inc.'s market cap?
Noile-Immune Biotech Inc.'s market capitalization is JPY 4.08B.
What does Noile-Immune Biotech Inc. do?
Noile-Immune Biotech Inc. researches and develops CAR-T cells for novel cancer immunotherapies. The company's product pipeline includes, NIB101, a target antigen for solid tumors; NIB102, a next-generation CAR-T cell therapy; NIB103, autologous CAR-T cell therapy for mesothelin (MSLN); NIB104, a PRIME technology against target antigens in solid tumors; ADAP01; AUTL01; and CHUG01. Noile-Immune Biotech Inc. was incorporated in 2015 and is headquartered in Minato, Japan.